Market Place
Sourcing Support
Three Complete Responses in Azer-Cel CAR T Phase 1b Blood Cancer Trial
03 Sep 2024 //
GLOBENEWSWIRE
Kincell takes on Imugene`s North Carolina plant, team for $6M
17 Apr 2024 //
FIERCE PHARMA
Imugene and Kincell Bio Partner on Manufacturing and Process Development
16 Apr 2024 //
GLOBENEWSWIRE
Imugene MAST High Dose Cohort Cleared For Bile Tract Expansion
15 Apr 2024 //
GLOBENEWSWIRE
Imugene highlights VAXINIA and HER-Vaxx at AACR
09 Apr 2024 //
GLOBENEWSWIRE
Phase 1 onCARlytics solid tumour trial advances to combination arm treatment
11 Mar 2024 //
GLOBENEWSWIRE
Imugene Highlights Recent Achievements
22 Feb 2024 //
GLOBENEWSWIRE
Imugene`s CF33-hNIS & MAST Study Featured at ASCO GI Cancers Symposium
18 Jan 2024 //
ACCESSWIRE
NeoImmuneTech and Imugene enter into strategic research collaboration
11 Dec 2023 //
PR NEWSWIRE
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy
20 Jul 2023 //
BUSINESSWIRE
FDA clears Imugene’s IND for solid tumours therapy trial
19 May 2023 //
CLINICAL TRIALS ARENA
Imugene’s onCARlytics combination with Celularity’s placental CYCART-19 T cells
10 Nov 2022 //
GLOBENEWSWIRE
City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial
17 May 2022 //
BUSINESSWIRE
Imugene Enters Trial Collaboration with Merck for HER-Vaxx + Pembrolizumab
14 Mar 2022 //
GLOBENEWSWIRE
City of Hope Opens Oncolytic Virus Clinical Trial in Advanced Breast Cancer
18 Nov 2021 //
BUSINESSWIRE
Imugene Announces Clinical Trial Supply Agreement with Merck KGaA
17 Nov 2021 //
GLOBENEWSWIRE
Imugene, Eureka Collaborate to Advance Oncolytic Virus and T-Cell Therapy
01 Nov 2021 //
BUSINESSWIRE
Imugene HER-Vaxx Immunotherapy Patent Granted in Japan
24 Sep 2021 //
BIOTECHDISPATCH
Imugene Announces HER-Vaxx Phase 2 Gastric Cancer Trial Data
01 Sep 2021 //
PRESS RELEASE
Imugene: Phase I Clinical Trial Update of Immunotherapy PD1-Vaxx
27 Aug 2021 //
FIRSTWORDPHARMA
Imugene inks partnership with Celularity to develop novel oncolytic virus
06 Aug 2021 //
PHARMABIZ
Imugene and Celularity Announce an Exclusive Strategic Partnership
04 Aug 2021 //
GLOBENEWSWIRE
Imugene says HER-Vaxx cancer vaccine induces 50% ORR in stomach cancer trial
06 Jul 2021 //
PMLIVE
Imugene says HER-Vaxx cancer vaccine induces 50% ORR in stomach cancer trial
05 Jul 2021 //
FIRSTWORDPHARMA
Imugene collaborator wins FDA Investigational NDA for CHECKvacc Ph1 trial
02 Jul 2021 //
PROACTIVEINVESTORS
Imugene has HER-Vaxx Phase 1B Data published in prestigious clinical cancer
29 Apr 2021 //
PROACTIVEINVESTORS
Imugene to Present HER-Vaxx Phase 2 Data at AACR21 Meeting
11 Mar 2021 //
LISTCORP
Imugene doses first patient in cohort-2 in phase-I clinical trial of PD1-Vaxx
11 Feb 2021 //
PROACTIVEINVESTORS
Imugene completes enrolment of first cohort of patients in Ph I clinical trial
18 Dec 2020 //
PROACTIINVESTOR
Imugene completes enrolment of first cohort of patients in PhI clinical trial
18 Dec 2020 //
PROACTIVEINVESTOR
Imugene receives FDA IND approval for phase-1 clinical trial of new checkpoint
02 Nov 2020 //
PROACTIVEINVESTOR
